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[571 ABSTRACT 
The present invention is drawn to a composition of matter 
comprising high viscosity sodium alginate, cellulose sulfate 
and a multi-component polycation. Additionally, the present 
invention provides methods for making capsules, measuring 
capsule permeability to immunologically-relevant proteins 
and treating disease in an animal using encapsulated cells. 
Over one thousand combinations of polyanions and polyca- 
tions were examined as polymer candidates suitable for 
encapsulation of living cells and thirty-three pairs were 
effective. The combination of sodium alginate, cellulose 
sulfate, poly(methy1ene-co-guanidine) hydrochloride, cal- 
cium chloride, and sodium chloride produced the most 
desirable results. Pancreatic islets encapsulated in this mul- 
ticomponent capsule demonstrated glucose-stimulated insu- 
lin secretion in vitro and reversed diabetes without stimu- 
lating immune reaction in mice. The capsule formulation 
and system of the present invention allows independent 
adjustments of capsule size, wall thickness, mechanical 
strength and permeability, and offers distinct advantages for 
immunoisolating cells. 
9 Claims, 15 Drawing Sheets 
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ENCAPSULATION SYSTEM FOR THE 
IMMUNOISOLATION OF LIVING CELLS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a continuation of provisional patent 
application U.S. Ser. No. 601015,593, filed Apr. 17, 1996, 
provisional patent application U.S. Ser. No. 601015,791, 
filed Apr. 17, 1996, and provisional patent application U.S. 
Ser. No. 601015,795, filed Apr. 17, 1996. 
FEDERAL FUNDING LEGEND 
This invention was produced in part using funds from the 
Federal government under grant no. NIH DK20593 and 
NASA contract NAS7-918. Accordingly, the Federal gov- 
ernment has certain rights in this invention. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates generally to the fields of 
endocrinology, protein chemistry and biomedical engineer- 
ing. More specifically, the present invention relates to a 
novel encapsulation system for the immunoisolation of 
living cells. 
2. Description of the Related Art 
Transplantation of cells to treat a variety of human 
diseases, such as diseases caused by hormone or protein 
deficiencies, is limited because transplanted cells are 
destroyed quickly by the recipient’s immune system. To 
overcome this limitation, it is desirable that hormone- or 
protein-secreting cells be enclosed in a semi-permeable 
membrane that would protect cells from immune attack, 
while allowing the influx of molecules important for cell 
functionisurvival and efflux of the desired cellular products 
(see refs. 1-7). 
The principle of immunoisolation or immunoprotection of 
cells for transplantation overcomes two main obstacles: 1) 
cell transplantation without the need for immunosuppression 
and its accompanying side effects, and 2) transplantation of 
cells from non-human species (xenograft) to overcome the 
limited supply of donor cells for such diseases as diabetes 
(refs. 8-12). Many diseases may be treated best by the 
regulated release of a cellular product (hormone, protein, 
neurotransmitter, etc.). Thus, a variety of cell types are 
candidates for transplantation of immunoisolated cells, 
including pancreatic islets, hepatocytes, neurons, parathy- 
roid cells, and cells secreting various clotting factors. 
One immunoisolation approach, encapsulation of pancre- 
atic islets, is under investigation by a large number of groups 
and has been successful in reversing chemically-induced 
diabetes in rodents and in a small scale human clinical trial 
(refs. 1-3, 6, 13-17). Most cell encapsulation currently 
utilizes modifications of the procedure originated by Lim 
and Sun in which the encapsulant is suspended in a polya- 
nionic aqueous solution and extruded by an air jetisyringe 
pump droplet generator into calcium ions (refs. 18 and 19). 
Poly(L-lysine), which is a cationic macromolecule, is then 
mixed with the hardened polyanionic gel, and a membrane 
is formed at the interface as a result of the ionic interaction. 
Because this is a binary system, however, all membrane 
parameters are tied to a single chemical complex. Attempts 
to optimize one parameter will affect all other parameters. 
The inability to adjust capsule parameters independently (for 
example, mechanical strength or permeability) has limited 
the success of this system (refs. 13 and 20). Capsules made 
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2 
with other binary polymer systems, such as Hydroxyethyl 
methacrylatehlethyl methacrylate ( H E M M M A )  suffer 
similar limitations (refs. 19, 21 and 22). 
The prior art is deficient in the lack of effective means of 
encapsulating and immunoisolating living cells. The present 
invention fulfills this long-standing need and desire in the 
art. 
SUMMARY OF THE INVENTION 
To overcome the limitations of the prior art, the present 
invention provides a new multicomponent polymer capsule 
which allows for modification of individual capsule param- 
eters such as capsule size, wall thickness, mechanical 
strength, permeability, and surface characteristics. The cap- 
sule characteristics can be adjusted and optimized for 
various, specific delivery systems, e.g., islet transplantation. 
Over one thousand combinations of polyanions and poly- 
cations were examined as polymer candidates suitable for 
encapsulation of living cells. Thirty-three combinations 
were found to be useable. The combination of sodium 
alginate (SA), cellulose sulfate (CS), poly(methy1ene-co- 
guanidine)hydrochloride (PMCG), calcium chloride 
(CaCl,), and sodium chloride (NaC1) produced the most 
desirable results. 
Pancreatic islets encapsulated in this multicomponent 
capsule reversed diabetes in both strepzotocin-induced and 
non-obese diabetic (NOD) mice. Encapsulated rat islets 
demonstrated glucose-stimulated insulin secretion in vitro 
and reversed diabetes in vivo in mice. The capsule formu- 
lation and system of the present invention allows indepen- 
dent adjustments of capsule size, wall thickness, mechanical 
strength and permeability, and offers distinct advantages for 
immunoisolating cells. 
In one aspect of the present invention, there is provided a 
composition of matter comprising high viscosity sodium 
alginate (SA-HV), cellulose sulfate, and a polycation. In a 
preferred embodiment of the present invention, the high 
viscosity sodium alginate and the cellulose sulfate are in a 
ratio of approximately 1:l .  Further, a preferred embodiment 
includes the high viscosity sodium alginate and said cellu- 
lose sulfate at a total concentration of 0.8 wt-% to 2.4 wt-%. 
In a more preferred embodiment, the high viscosity sodium 
alginate and the cellulose sulfate are at a total concentration 
of 1.0 wt-% to 1.2 wt-%, in the ratio of 1:l .  
In addition, an embodiment may be where the individual 
components of the polycation are at a concentration of 0.5 
wt-% to 5.0 wt-%. A more preferred embodiment would 
include where each component of the polycation is at a 
concentration of 0.8 wt-% to 2.8 wt-%. 
In addition, the present invention may include a polyca- 
tion comprised of poly(methy1ene-co-guanidine) 
hydrochloride, calcium chloride and sodium chloride. In a 
most preferred embodiment, the poly(methy1ene-co- 
guanidine)hydrochloride is at a concentration of about 1.8 
wt-%, the calcium chloride is at a concentration of about 1.0 
wt-%, and the sodium chloride is at a concentration of about 
Another aspect of the present invention includes a method 
of making capsules for the immunoisolation of cells com- 
prising the steps of  providing a continuously-replenished 
polycation stream in a multiloop reactor; dropping 
uniformly-sized drops of anion solution and cells into said 
polycation stream; allowing said polycation stream to carry 
said drops, wherein said polycation and said anion react to 
form a capsule; collecting said capsules in a large excess of 
buffer; placing said capsules on a filter; and re-rinsing said 
capsules in buffer. 
0.9 wt-%. 
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In yet another aspect of the present invention, there is 
provided a method for measuring capsule permeability to 
immunologically-relevant proteins, comprising the steps of  
encapsulating an antibody and an appropriate carrier in a 
capsule formulation to be tested; equilibrating said capsule 
and encapsulated antibody in a buffer; adding labeled said 
immunologically-relevant proteins to said buffer; and mea- 
suring an amount of said immunologically-relevant proteins 
which entered said capsule. In a preferred embodiment, the 
carrier is protein A-sepharose, and the immunologically 
relevant protein is an immunoglobulin. 
In an additional aspect of the present invention, there is 
provided a method of treating disease in an animal, com- 
prising the steps of  encapsulating cells, that secrete a 
protein or hormone that emeliorates said disease, in a 
capsule, wherein said capsule is comprised of high viscosity 
sodium alginate, cellulose sulfate, and a polycation; and 
transplanting said encapsulated cells into said animal, 
wherein said transplated encapsulated cells secrete said 
protein or hormone. A particular embodiment of this aspect 
of the invention is drawn to treating diabetes using pancre- 
atic islet cells. Such cells may be encapsulated in a capsule 
wherein the high viscosity sodium alginate and the cellulose 
sulfate are at a total concentration of 1.0% wt-% to 1.2 wt-% 
and in a ratio of approximately 1:1, and the polycation is 
comprised of poly(methy1ene-co-guanidine)hydrochloride 
at a concentration of about 1.8 wt-%, the calcium chloride is 
at a concentration of about 1.0 wt-%, and the sodium 
chloride is at a concentration of about 0.9 wt-%. 
Other and further aspects, features, and advantages of the 
present invention will be apparent from the following 
description of the presently preferred embodiments of the 
invention given for the purpose of disclosure. 
BRIEF DESCRIPTION OF THE DRAWINGS 
So that the matter in which the above-recited features, 
advantages and objects of the invention are attained and can 
be understood in detail, more particular descriptions of the 
invention may be had by reference to certain embodiments 
thereof which are illustrated in the appended drawings. 
These drawings form a part of the specification. It is to be 
noted, however, that the appended drawings illustrate pre- 
ferred embodiments of the invention and therefore are not to 
be considered limiting in their scope. 
FIG. 1 shows viscosity as a function of polyanion con- 
centration in phosphobuffered saline (PBS) at 21" C. 
SA(HV) (filled square); CS,+; mixture of CS and SA(HV) in 
the ratio of 1:1, filled circle. 
FIG. 2 shows the capsule prepared in the absence of 
sodium chloride; CS 0.6 wt-%/SA 0.6 wt-%, 0.6 wt % 
PMCG, and 0.5 wt % CaCl,, The reaction time was 90 
seconds. FIG. 2 A  results after the first wash, FIG. 2B: 
results after storage in PBS. The bar is 0.5 mm. 
FIG. 3 shows the capsule prepared in the presence of 
sodium chloride; CS 0.6 wt-%/SA 0.6 wt-%, 0.6 wt % 
PMCG, 0.5 wt % CaCl,, and 0.9 wt % NaC1. The reaction 
time was 90 seconds. FIG. 3 A  results after the first wash, 
FIG. 3B: results after storage in PBS. The bar is 0.5 mm. 
FIG. 4 shows the capsules prepared by the complexation 
reaction; FIG. 4 A  capsules prepared in a beaker, with a 
reaction time of 30 seconds and a collection time of 30 
seconds; FIG. 4B: capsules prepared in the chemical reactor, 
with a reaction time of 45 seconds. The bar is 0.5 mm. 
FIG. 5 shows the membrane thickness at different stages 
of capsule processing. See TABLE I11 for the conditions of 
capsule preparation: after first wash in PBS, 0 ; after citrate 
treatment, open circle; after 24 hrs in PBS,+. 
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FIG. 6 shows that capsule mechanical stability is greatly 
increased. Mechanical burst strength of capsules as a func- 
tion of wall thickness was measured by applying an uniaxial 
load. The solid square is the mechanical burst strength of 
5 sodium alginate-poly-(L-Lysine) SA/PLL capsules that were 
produced (ref. 37). The circles are the mechanical burst 
strength of SA/CS/PMCG capsules. The solid circle is the 
mechanical strength of 0.6% CS-0.6% Alginate capsules, 
and the open circle is 0.9% CS-0.9% Alginate capsules. 
MT=membrane thickness, d=diameter. 
FIG. 7 shows the pore size distribution of capsular mem- 
branes of the present invention. Apparent pore size distri- 
bution (PSD) of SA/CS/PMCG/CaCl,/NaCl microcapsules 
was estimated based on dextran viscosity radius R,. The 
cumulative PSD (dotted line) and differential PSD (solid 
line) are shown. The SA/CS/PMCG capsules were prepared 
from the mixture of 0.6% SA and 0.6% CS; the polycation 
solution contained 1.8% PMCG, 1% CaC1, and 0.9% NaCl 
with a one minute reaction time. The exclusion limit of this 
capsule, determined by SEC with dextran standards, was 
FIG. 8 shows capsule ermeability to IgG. Time course of 
rabbit anti-mouse IgG-1 binding to free and encapsulated 
protein-Asepharose (capsules with 230 kDa exclusion limit) 
are shown. Symbols: 18 pL of free protein-A sepharose gel 
2s (square), capsules loaded with 18 pL of protein-A sepharose 
gel (circle), empty capsules (triangle). 
FIG. 9 shows insulin secretion by encapsulated pancreatic 
islets. Insulin response of islets in response to the glucose 
challenge as a function of time was measured in a cell 
30 perifusion system. Free and encapsulated islets (800 pm 
capsule diameter, 100 pm membrane thickness, exclusion 
limit 230 kDa) were cultured at 24" C. in RPMI 1640 
medium supplemented with 5 mM glucose and 10% fetal 
calf serum for 24 hours prior to the perifusion. Results from 
35 experiments with unencapsulated islets (squares) and encap- 
sulated islets (circles) are shown. The black bar at the top of 
the graph shows the stimulation period with 20 mM glucose 
and 0.045 mM IBMX. 
FIG. 10 shows the biocompatibility of empty capsules. 
40 The two capsules shown were prepared under identical 
processing steps, but were different in PMCG concentration 
(right panel-1.8% PMCG; left panel-1.0% PMCG) and were 
transplanted intraperitoneally into normal C57B16 mice. 
Capsules were retrieved 30 days later and photographed. 
45 FIG. 10A shows capsules prior to transplantation (black bar 
is 340 pm) and FIG. 10B shows capsules retrieved from 
normal mice (black bar is 340 pm). 
FIG. 11 shows that the transplantation of encapsulated rat 
islets reverses diabetes. FIG. 1 1 A  Approximately 1000 
SO encapsulated rat islets (0.8 mm capsule with 0.1 mm wall 
thickness and exclusion limit of 230 kDa) were transplanted 
intraperitoneally into diabetic C57iB16 mice (strepzotocin- 
induced). The mean and standard deviation of blood sugars 
of non-diabetic animals (measured using a One-touch 
ss glucometer) were plotted against the number of days fol- 
lowing transplantation. Of the sixteen diabetic mice which 
received transplants, the number of non-diabetic animals at 
selected time points is shown in parentheses. Of the eight 
animals with normal blood sugars 110 days following 
60 transplantation, two later became diabetic while six were 
still normoglycemic 300 days following transplantation. 
FIG. 11B: Encapsulated rat islets were transplanted into the 
peritoneal cavity of female NOD mice which had developed 
spontaneous diabetes by the age of 20 weeks. Of the four 
65 diabetic mice that received transplants, the number of non- 
diabetic animals at selected time points is shown in paren- 
theses. 
10 
20 230 kDa (ref. 35). 
l 
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FIG. 12 shows that the encapsulated islets have long-term 
function and biocompatibility. FIG. 1 2 A  the viability of 
encapsulated islets retrieved one year following transplan- 
tation into diabetic C57/B16 mice was assessed in the cell 
perifusion apparatus as described in FIG. 4. The bar at the 
top shows the stimulation period with 20 mM glucose and 
thickness, mechanical strength, membrane permeability, and 
surface characteristics based on feedback from biological 
results in vitro and in vivo. 
The following examples are given for the purpose of 
illustrating various embodiments of the invention and are 
not meant to limit the present invention in any fashion, 
5 
0.045 mM IBMX. For comparison, insulin secretion of 
unencapsulated islets (squares), freshly encapsulated islets 
(diamonds), and retrieved encapsulated islets (circles) is 
shown. FIG. 12B: retrieved encapsulated islets were photo- i o  
graphed. The black bar is equal to 340 mm. 
EXAMPLE 1 
Assessment of Capsule Permeability 
TO assess capsule Permeability to imm~nologicallY- 
relevant proteins like IgG, protein A-sepharose (PAS, Sigma 
Chemicals, St. Louis, Mo.) was encapsulated. Empty cap- 
sules and capsules containing -18 pl of packed PAS were 
equilibrated in phosphate-buffered saline (PBS) with 0.2% 
Tween 20 and 0.2% bovine serum albumin. Iodinated IgG 
(approximately 10,000 cpm; New England Nuclear, 
Wilmington, Del.) was added to the PBS and aliquots of PAS 
were removed at selected time points over 24 hours. After 
removal at each time point, the encapsulated PAS was 
2o washed five times with 4 ml of PBS. The amount of IgG that 
had entered the capsule was quantitated in a gamma counter. 
Unencapsulated or free PAS served as a positive control. 
measuring entry of almost any protein since the only 
requirements are an antibody against the protein of 
would be preincubated 
with the antibody before encapsulation-and the ability to 
radiolabel the protein, 
DETAILED DESCRIPTION OF THE 
INVENTION 
In the description of the present invention, a following 
abbreviations may be used: SEC, size exclusion chromatog- 
raphy; SA=sodium alginate; CS, cellulose sulfate; PMCG, 
poly(methy1ene-co-guanidine); PAS, protein A sepharose; 
PSD, pore size distribution; PBS, phosphate-buffered saline; 
HBSS, Hank’s Balanced Saline Solution; IBMX, 3-isobutyl- 
1 -methyl-Xanthine. 
matter comprising various anion and polycation mixtures. A 
particularly workable combination is that of high viscosity 
sodium alginate, cellulose sulfate and a multicomponent 25 
polycation. 
It is specifically contemplated that pharmaceutical com- 
positions may be prepared using protein-secreting cells 
encapsulated in the novel capsules of the present invention. 
In such a case, the pharmaceutical composition may com- 30 Assessment of Insulin Secretion 
person having ordinary skill in this art readily would be able 
to determine, without undue experimentation, the appropri- 
tration of the capsule of the present invention. 
Additionally, the present invention provides methods for 
making capsules, measuring capsule permeability to 
immunologically-relevant proteins and treating disease in an 
animal using encapsulated cells. 
Immunoisolation is based on the premise that a membrane 
can protect secreting cells, such as pancreatic islets, from the 
host immune system and yet allow entrance and exit of 
substances required for cell maintenance and stimulation of 
protein of hormone secretion. Although the concept of 45 
immunoisolation is straightforward, stringent biologic and Animal Studies 
physical criteria must be met for long-term survival and Pancreatic islets were isolated from male Sprague- 
function of the immunoisolated cell within a biologic host. Dawley rats (250-275 g, Harlan), Briefly, the pancreatic 
Immunoisolation devices must be biocompatible with the duct was inflated with a solution of Hank’s Balanced Saline 
host and with the transplanted cell and must allow entry of 50 Solution (HBSS) containing collagenase (Boehringer- 
oxygen and nutrient molecules required for health of the Mannheim, Collagenase P). Groups of 3 pancreases were 
enclosed cell. The promise of immunoisolation has lead to digested in 2 mg collagenase/pancreas in HBSS for 6-13 
the development of a wide array of devices including minutes at 37” c, using a wrist-action shaker, The digestion 
microcaPs~les, macrocaPs~les, hollow fibers, tubular was stopped by the addition of cold HBSS with 10% 
membranes, intravascular devices, and flat sandwich 5s Newborn Calf Serum and shaken vigorously for 10-15 
pouches. Encapsulation of cells within microcapsules has seconds, The digested material was washed three times with 
been most WidelY-used, but difficulties with capsule cold HBSS and filtered through a wire mesh cell strainer to 
biocomPatibilitY, capsule strength, and the inability to define remove undigested material. Pancreatic islets were separated 
and modify parameters critical for immunoisolation and cell using a Histopaque-1077 gradient and stored in University 
survival has prevented this technology from achieving its 60 of Wisconsin storage solution (“Viaspan”) for 19-24 hours 
full potential. before encapsulation. 
Using a new combination of polymers and new encapsu- Encapsulated rat islets were transplanted into the perito- 
lation technology, the present invention provides a multi- neal cavity of diabetic mice (either strepzotocin-induced or 
component capsule formed by polyelectrolyte complex- NOD mice). Diabetes was induced in normal C57/B16 mice 
ation. This complexation has been evaluated in vitro and in 65 by the intraperitoneal injection of strepzotocin (200 mg/kg) 
vivo. This new capsule and encapsulation technology allows 3-7 days prior to transplantation of encapsulated islets. 
for a systematic modification of capsule size, membrane NOD mice were purchased from Taconic Laboratories 
The present invention is directed to a compositions Of This method of permeability assessment can be adapted for 
such a case, the 
EXAMPLE 2 
prise the cells and a pharmaceutically acceptable matrix, A Insulin secretion by encapsulated rat islets was evaluated 
in a cell perifusion apparatus with a flow rate of 1 mliminute 
with RPMI 1640 with 0.1% BSA as a Perifusate. EncaPsu- 
35 and the column flowthrough discarded. Fractions of perifu- 
sate were collected at three-minute intervals during a 30 
minute perifusion of 2 mM glucose, a 30 minute perifusion 
Of 2o mM g1ucose+0.045 mM IBMX3 and a 6o minute 
perifusion of 2 mM glucose. Samples were assayed in 
40 duplicate for insulin using Coat-a-Count kits (Diagnostic 
Products Corporation, Los Angeles, Calif.) with a rat insulin 
standard. The amount of insulin secreted was normalized for 
the number Of 
ate cell number, matrix composition and routes of adminis- lated islets were perifused with 2 mM glucose for 30 minutes 
EXAMPLE 3 
5,997,900 
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(Germantown, N.Y.) and bred in microisolator cages with 
autoclaved bedding and water. Between 18-24 weeks of age, 
50-75% of females from this colony became diabetic. When 
diabetes was present for 2-4 weeks, female NOD mice 
received a transplantation of encapsulated islets. Approxi- 
mately 1000 encapsulated rat islets (0.8 mm capsule with 0.1 
mm wall thickness and an exclusion limit of 230 kDa) in a 
packed capsule volume of 0 .24 .5  ml were sterilely trans- 
planted intraperitoneally into metofane-anesthetized mice. 
The blood sugar of the mice was measured using a One- 
touch glucometer using blood obtained from the retroorbital 
plexus or a tail vein. 
EXAMPLE 4 
Capsule Development: Polymer Screening 
To develop new capsule formulations, over one thousand 
combinations of water-soluble polyanions and polycations 
were tested. Adroplet of each polyanion (3-5 mm diameter) 
was manually dropped into a beaker of polycation solution. 
Formation of a capsule was noted by visual observation 
under a microscope. Acrude estimate of mechanical stability 
of the capsule was obtained by manual compression of 
capsules. For those pairs that showed promise in the screen- 
ing tests, the effects of pH, molecular weight of the polymer, 
and charge density on capsule formation were examined 
(data not shown). Polymer pairs that formed capsules were 
also tested for biocompatibility using an in vitro culture 
system with rat insulinoma cells (RIN 1046-38 cells from 
American Tissue Culture Collection, Rockville, Md.). The 
growth rate of RIN cells, cultured in the presence of either 
a solution or a membrane of the polymer of interest, was 
used to select polymers for further investigation. Twenty- 
one multicomponent membrane systems were studied 
(TABLE I). A combination of sodium alginate (SA), cellu- 
lose sulfate (CS), polymethylene-co-guanidine (PMCG), 
CaCl,, and NaCl was found to be most effective. 
TABLE I 
Results ot the Screening of Multicomponent Membrane Systems. 
Polyanion Blend Polycation Blend 
HV AlginateiCellulose Sulfate Polymethylene-co-Guanidineicalcium 
HV AlginateiCellulose Sulfate Polydimethylamine-co-epichlorhydrin- 
HV AlginateiCellulose Sulfate PolyvinylamineiCalcium Chloride 
HV AlginateiCellulose Sulfate PolylysineiCalcium Chloride 
HV AlginateiCellulose Sulfate Polyvinylamine(LMW & HMW) 
Chloride 
modified quaternary 
AlginateiCellulose Sulfate/ 
C o 11 age n 
Alginateicarrageenan kappa/ 
LTM-Agarose 
Alginateicarrageenan kappa 
and lambda 
Alginateicarrageenan kappa 
AlginateiCellulose Sulfate 
Alginate 
AlginateiLTM Agarose 
HV AlginateiGellan 
HV AlginateiGellan 
Carrageenan kappa and iota 
Carrageenan kappa/ 
Hyaluronic Acid 
Carrageenan kappa/ 
Hyaluronic Acid 
Carrageenan kappa/ 
Chondroitin Sulfate A 
. .  
Polymethylene-co-guanidineicalcium 
Chloride 
ProtamineiCalcium and Potassium 
Chloride 
ProtamineiCalcium and Potassium 
Chloride 
ProtamineiCalcium and Potassium 
Chloride 
SpermineiPolydimethylene-co-guanidine 
SpermineiPolydimethylene-co-guanidine 
PolybreneiCalcium Chloride 
ProtamineiCalcium and Potassium 
Chloride 
LysozymeiCalcium Chloride 
ProtamineiCalcium and Potassium 
Chloride 
ProtamineiCalcium and Potassium 
Chloride 
Polybrene 
Polyvinylamine(LMW & HMW) 
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TABLE I-continued 
Results ot the Screening of Multicomponent Membrane Systems. 
Polvanion Blend Polvcation Blend 
LE-PectiniCellulose Sulfate 
LE-PectiniCellulose Sulfate 
LE-Pectin 
LE-PectiniLTM-Agarose 
Xanthan 
Xanthan 
XanthaniAlginate 
XanthaniCellulose Sulfate 
Xanthan 
Carboxymethylcellulose 
(HMW)/Cellulose Sulfate 
CMC(HMW)/Hyaluronic 
Acid 
CMC(HMW)/Hyaluronic 
Acid 
CMC(HMW)/Hyaluronic 
Acid 
CMC(HMW)/Hyaluronic 
Acid 
CMC(HMW)/Carrageenan 
lambda 
Polymethylene-co-guanidineicalcium 
Chloride 
Quart-PolyamineiCalcium Chloride 
Quart-PolyamineiCalcium Chloride 
PoybreneiCalcium Chloride 
PolylysineiSpermine 
PolylysineiPolyallylamine 
Polymethylene-co-guanidine 
Polymethylene-co-guanidine 
PolyvinylamineiPol yethyleneimine- 
hydroxyethylated 
Chitosan(LMW)/Polyvinylamine 
Chitosan(LMW)/Polyethyleneimine 
hydroxylethylated 
Chitosan(LMW)/pDADMAC 
Chitosan(LMW)/Quaternary-Polyamine 
Chitosan(LMW)/Polydimethylamine-co- 
epichlorhydrin modified Quaternary 
Polymethylene-co-guaridine 
LE: Low Esterified, 
LTM: Low Temperature Melting, 
MMW Medium Molecular Weight, 
LMW Low Molecular Weight, 
HMW High Molecular Weight, 
H V  High Viscosity 
EXAMPLE 5 
Capsule Processing 
Capsules may be made in a chemical reaction chamber. A 
multi-loop chamber reactor filled with cation solution is 
particularly advantageous. The cation solution bath was fed 
by a cation stream which continuously replenished the 
solution and carried away the anion drops being introduced 
into the chamber. S N C S  droplets, with pancreatic islets 
enclosed, entered the PMCGICaC1,INaCl stream at an 
oblique angle, so as to minimize the islet decentering and 
drop deformation problem associated with impact (refs. 
24-28). The droplets were then carried into the multi-loop 
reactor by the polycation stream. The reactor used must 
allow for adjustment of reaction time and negate gravita- 
tional effects. These features facilitate tight control of cap- 
sule sphericity, membrane thickness and uniformity. Using 
such a reactor, one can produce capsules with diameters 
from 0.5 mm to 3.0 mm and membrane thicknesses from 
0.006 mm to 0.125 mm. 
EXAMPLE 6 
Chemicals 
The polymers used were: high viscosity sodium alginate 
(SA-HV) from Kelco (San Diego, Calif.), cellulose sulfate, 
sodium salt (CS) from Janssen Chimica (Geel, Belgium), 
poly(methy1ene-co-guanidine)hydrochloride (PMCG) from 
Scientific Polymer Products Inc. (Ontario, N.Y.), dextran 
sulfate from Sigma (St. Louis, Mo.) and low viscosity 
sodium alginate (SA-LV) from Kelco (San Diego, Calif.). 
Streptozotocin (STZ) was purchased from Sigma (St. Louis, 
Mo.), collagenase P from Boehringer-Mannheim 
(Indianapolis, Ind.) and phosphate buffered saline (PBS) 
from Gibco (catalogue #21600-069). All salts were reagent 
grade from Fisher or Aldrich. 
High viscosity sodium alginate is a product isolated from 
the seaweed Macvocystis Pyvifeva. According to information 
5,997,900 
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provided by the manufacturer, it consists of 40.6% of 
mannuronic acid blocks, 17.7% of guluronic acid blocks and 
the rest is the alternating copolymer of mannuronic and 
guluronic units (ref. 29). The average number of guluronic 
units forming the blocks is 6.0 (ref. 30). The average 
molecular weight of SA-HV equal to 4.6~10' was deter- 
mined by viscosimetry. The measurement was done in 0.1 M 
aqueous NaCl at 20" C. by using Mark-Houwink parameters 
a=1.00 and K = ~ . O X ~ O ~ ~  cm3/g according to work of 
SmidsrBd (ref. 30). These parameters were used for sodium 
alginate isolated from Macrocystis pyrifera although they 
were found for sodium alginate isolated from Laminaria 
digitata (ref. 31). However, as shown by Martinsen et al., the 
composition characteristics of this alginate and that isolated 
from Macrocystis pyrifera are almost identical; hence, one 
can assume they both have the same solution properties (ref. 
30). The viscosity of SA-HV in phosphate-buffered saline 
solution (PBS) as a function of concentration at 21" C. is 
given in FIG. 1. 
For cellulose sulfate, sodium salt, it was determined that 
the viscosity average molecular weight of CS was equal to 
1 . 2 ~ 1 0 ~ .  Measurements were performed in 0.5 M aqueous 
NaCl solution at 25" C., and Mark-Houwink parameters 
K = 6 . 3 7 ~ 1 0 - ~  cm3/g and a=0.94 from Kishino et al. were 
used (ref. 32). The degree of sulfation (DS) obtained by 
elemental analysis (Microlab, Norcross, Ga.) was equal to 
2.6 (19.6 wt.-% of sulfur). The viscosity of a semidilute 
solution of CS in PBS as a function of concentration is 
shown in FIG. 1 which also depicts the viscosity/ 
concentration dependence of SA-HVICS mixture in PBS 
(weight ratio 1:l). 
Poly(methy1ene-co-guanidine)hydrochloride is a product 
of a polycondensation reaction of guanidine (or 
cyanoguanidine) with formaldehyde and ammonium chlo- 
ride (ref. 33). The molecular weight, provided by the 
manufacturer, is 5000. It is supplied as a concentrated 
(35-50wt.-%) solution in water. Residual formaldehyde was 
removed by a freeze-drying technique followed by drying in 
vacuum at 50" C. for 48 hours. Based on the results from 
elemental analysis (Microlab, Norcross, Ga.), the amount of 
S 
10 
1s 
20 
2s 
30 
3 s  
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nitrogen, incorporated in both amine and imine groups, is 
5&60 mole-% which determines high basicity of this com- 
pound. 
EXAMPLE 7 
Individual Role of the Components on the Capsule Forma- 
tion Process 
TABLE I1 comprises the summary of the membrane 
formation process when a compound (or compounds) of the 
same charge are combined with the compound (or 
compounds) of the opposite charge. This experiment illus- 
trates how the individual components affect the capsule 
formation process and the final properties of the capsule. 
The effect of NaCl is shown separately. Properties at three 
successive stages of the capsule processing are described: 1) 
after collection of the polyanion drops and the first wash in 
PBS, 2) after capsule treatment in citrate, and 3) after storage 
in PBS. 
Experiments 1 4  in TABLE I1 describe the interactions of 
SA-HV with CaC1, and PMCG as well as when these cation 
compounds are used either as a mixture or individually in 
two successive reaction steps. Experiment 1 represents the 
classical SNCaC1, bead formation. Note when the calcium 
ions are removed by sodium citrate treatment, the capsules 
dissolved. Capsules formed in Experiment 2 ruptured 
shortly after their preparation and storage in PBS. Stable, yet 
rather swollen and fragile capsules resulted from Experi- 
ments 3 and 4. 
Experiments 5 to 8 in TABLE I1 reveal the reactivity of 
CS toward the counterions at the same conditions as in the 
experiments for SA-HV. Reaction with CaC1, (Experiment 
5) gave a precipitate which dissolves slowly in PBS, and 
rapidly in the sodium citrate solution. Soft, shrunk and stable 
capsules were obtained by reaction of CS with PMCG 
(Experiment 6). When the solution of the PMCGICaCl, 
mixture was used in a single step reaction (Experiment 7), 
the capsules obtained were soft and stable and possessed a 
fine sponge-like structure. The capsules formed in Experi- 
ment 8 were made following the procedure in Experiment 5, 
but, due to instability of CSICaCl, 
TABLE I1 
Summarv of Capsule formation process and role of individual components. 
PMCG 
SA-HV CS CaC1, 1 wt:% SO mM Sodium Storage in 
1 wt:% 1 wt:% 1 wt:% 0.9% NaCl First wash citrate PBS 
Expt PBS PBS H,O pH7.S inPBS (5 min) (24 hrs) 
1 1  
2 1  
3b I 
4c I 
s -  
6 -  
7b - 
8 C  - 
9a I 
l o a  1 
- T, beads 
slowly 
dissolved 
shrunk 
I partially 
I beads 
I beads 
- shrunk, slowly 
I shrunk, stable 
I shrunk, stable 
I shrunk, stable 
- beads, slowly 
I irregular 
dissolved 
dissolved 
shape 
quickly dissolved - 
- swelling, ruptured 
swelling T, swollen, stable, 
swelling T, swollen, stable, 
quickly dissolved - 
- NT, shrunk, stable 
shrunk, stable ST, shrunk, stable, 
fine sponge-like 
shrunk, stable NT, shrunk, stable, 
coarse sponge-like 
quickly dissolved - 
- swelling, ruptured 
fragile 
fragile 
11 
TABLE 11-continued 
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Summarv of Capsule formation process and role of individual components. 
PMCG 
SA-HV CS CaC1, 1 wt:% SO mM Sodium Storage in 
1 wt:% 1 wt:% 1 wt:% 0.9% NaCl First wash citrate PBS 
Expt PBS PBS H,O pH7.5 inPBS (5 min) (24 hrs) 
l l a , b  1 I I I ST beads ST capsules, ST, strong, stable, 
stable visible ST 
membrane 
12a ,c  1 I I I ST beads ST capsules, ST, strong, stable, 
stable visible membrane: 
precipitated core 
T, ST, NT - transparent, semitransparent, nontransparent 
"SA-HVICS mixture contained 1 wt:% SA-HV and 1 wt:% CS in PBS 
bPMCGICaC1, mixture contained 1 wt:% PMCG, 1 wt:% CaC1, in 0.9 wt:% NaCl at pH 7.5 
'PMCG reaction is a second step following the bead formation using CaC1, in the first step 
complex in PBS, instead of being washed in PBS they were 
drained from CaC1, solution and transferred directly into 
PMCG. The resulting capsules showed a coarse sponge-like 
structure. 
Finally, the third group of experiments, experiments 9 to 
12 in TABLE 11, represent the situation when both polyanion 
components, SA-HV and CS, participate in the capsule 
formation process. The SA-HVICSICaCl, beads 
(Experiment 9) showed a slightly lower transparency than 
those obtained in Experiment 1 (SNCa), but were more 
transparent than CSICaCl, beads from Experiment 5. 
Similarly, as in Experiment 2, capsules formed in Experi- 
ment 10 were unstable in PBS. In Experiment 11, the 
mixture of SA-HVICS was interacted in a single step 
process with the PMCGICaCl, mixture. In this case, the 
capsules were spherical, stable, strong, semitransparent, and 
exhibited a distinct membrane. When the capsule formation 
procedure was divided into two steps so that PMCG reacted 
with pre-formed SA-HVICSICaCl, beads (Experiment 12), 
the resulting capsules were weaker than those made in 
Experiment 11, and their membrane was thinner and less 
transparent. The capsule core is more opaque than that in 
Experiment 11 and, after a short time, a precipitate is seen 
in the capsule core. 
The results in TABLE I1 led to a study of the polyelec- 
trolyte system represented by Experiment 11: capsule for- 
mation based on the principle of a single step interaction of 
SA-HVICS mixture with polycation mixture. By varying the 
overall concentration of the polyanion mixture ranging from 
0.8 wt.-% to 2.4 wt.-% at a different relative component 
ratio, the optimum composition and concentration of the 
polyanion solution has been determined. The optimum 
weight ratio CS/(SA-HV+CS) was found to be approxi- 
mately 0.5. Augmentation in CS content showed a negative 
impact on capsule sphericity, smoothness and transparency. 
On the other hand, capsules prepared at low CS/(SA-HV+ 
CS) ratio were less mechanically strong. A preferred capsule 
shape was achieved at the minimal total polyanion concen- 
tration 1.0 wt.-% and a capsule of preferred strength was 
obtained when the total polyanion concentration was at 1.2 
wt.-%. The studies described below utilized the single-step 
interaction of the polycation mixture with the mixture of 
polyanions where SA-HVCS was 1: l .  
The attributes of the polycation solution are closely bound 
with other variables such as concentration and composition 
of the polyanion solution, capsule size, and reaction time. 
Composition of cation solution was tested over a large 
concentration range of all components with the reaction time 
varying from a few seconds to several minutes. An increased 
2o ratio of PMCGICaCl, results in the capsules with lower 
transparency, a thicker membrane and higher mechanical 
strength. Moreover, the complexation reaction of these two 
cation compounds with a given polyanion matrix is signifi- 
cantly influenced by the presence of sodium chloride, as 
EXAMPLE 8 
25 demonstrated below. 
Effect of NaCl 
FIG. 2 shows capsules after a first wash and after storage 
in PBS following the citrate treatment, respectively. In this 
30 case, the cation solution did not contain sodium chloride. 
Capsule deformation seen at the first stage of the process is 
transferred into the quality of the membrane at the final stage 
where membrane defects are strongly apparent as ridges and 
wrinkles (FIG. 2A). On the other hand, much higher capsule 
35 quality is obtained at both stages of capsule formation when 
sodium chloride is present in cation solution (FIG. 3). The 
membrane is smooth and free of defects. Note that under 
these conditions the membrane is clearly visible only after 
calcium removal. 
EXAMPLE 9 
40 
Capsule formation 
FIG. 4 compares the capsules prepared by two different 
techniques. In the first case (FIG. 4A), capsules were col- 
lected for 30 seconds in a beaker containing polycation 
solution and then were left to react with the polycation for 
another 30 seconds (the average reaction time for the entire 
batch was 45 seconds). This represents the preferred con- 
ditions for preparing a large batch of capsules, which 
involves changing the collecting cation solution every 30 
seconds followed by the washing step. 
In the second case, the capsules were continuously pro- 
duced in the chemical reactor, with the residence time of 
each capsule being 45 seconds. The capsules were collected 
55 for 60 seconds in a large excess of PBS. After collection, 
they were washed on a screen to remove any residual 
polycation and transferred to fresh PBS. Capsules shown in 
FIG. 4A exhibit much higher polydispersity in size and 
membrane thickness than those prepared by using the reac- 
tor (FIG. 4B). For these experiments, the total concentration 
of polyanion solution was 1.2 wt.-% and the cation solution 
contained 1.8 wt.-% PMCG, 1.0 wt.-% CaC1, and 0.9 wt.-% 
NaCl at pH 7.5. 
EXAMPLE 10 
65 Capsule Size and Membrane Thickness 
The results on the measurements of capsule size and 
membrane thickness at the different stages of capsule for- 
4s 
so 
60 
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mation are listed in TABLE I11 and FIG. 5 .  The data on the 
membrane thickness were not optically corrected, and the 
measurements of capsule diameter were accurate within 3%. 
These parameters were examined as a function of reaction 
time at the overall polyanion concentration 1.2 wt.-%. 
since the polyanion drop size was kept constant through- 
reaction time on the swelling of capsules at the initial stage 
certain reaction time, the network density becomes high i o  
enough to prevent the capsule from swelling; consequently 
the capsule size does not change. Concerning the next stages 
of capsule processing, the capsules prepared at shorter 
reaction times (less than 30 seconds) gradually 
chromatography (SEC) with dextran molecular weight stan- 
dards (ref. 35); and 2) a newly-developed method to assess 
permeability of a series of biologically-relevant proteins 
using encapsulated Protein A-sePharose (PAS). BY maniPu- 
5 lating component concentration to control capsule perme- 
ability and using the above-mentioned methodologies to 
permeab (40 kDa-230 kDa, based On dextran exclu- 
The apparent pore size of the capsular membrane was 
determined by size exclusion chromatography (SEC) which 
measured the exclusion of dextran solutes from the column 
packed with microcapsule (ref. 35). Using neutral polysac- 
charide molecular weight standards makes it possible to 
evaluate membrane properties under conditions where sol- 
ute diffusion is controlled by its molecular dimension only. 
Based on the measured values of solute size exclusion 
coefficients (KSEc) and known size of solute molecules, one 
can estimate the membrane pore size distribution (PSD) 
(FIG. 7). The differential PSD calculated for the microcap- 
sules with 230 kDa exclusion limit :bowed a maximum at a 
(s) First wash in PBS (5 min) (24 hrs) viscosity radius R, equal to 50 A. As determined from 
molecular weight calibration, the capsular membrane 
excluded dextran molecules with molecuF weight above 5 1.12 1.16 1.21 
10 1.10 1.12 1.14 
230 kDa which corresponds to R,2117 A (shaded area in 
FIG. 7). 
1s 1.04 1.08 1.11 
20 1.08 1.11 1.13 
30 1.07 1.11 1.13 To assess capsule permeability to immunologically- 
relevant proteins, a new method involving encapsulated 4s  1.04 1.04 1.01 60 1.04 1.01 1.01 
protein A-sepharose (PAS) was developed. IgG readily 
entered capsules with the 230 kDa exclusion limit (FIG. 8). 
swelled after being transferred to sodium citrate and later 30 The 110 kDa capsule, but not the 40 kDa, was permeable to 
during the storage in PBS. At higher reaction time, the IgG (data not shown). The SA/PLL capsules used by many 
capsule swelling was negligible-ven a slight shrinking have an exclusion limit of 100 kDa based on dextyn 
was observed. measurements (ref. 35), which corresponds to a R, of 78 A. 
FIG. 5 shows that reaction time has a great impact on the It is noteyorthy that the molecular size of IgG reported (ref. 
thickness of the capsular membrane, a Property which 3s 36) is 52 A and thus according to the calculated PSD in FIG. 
determines finally capsule mechanical stability. For a given 7, the passage of IgG across the capsular membrane with 
capsule size, the mechanical strength increases proportion- 230 kDa exclusion limit would be expected, Even though 
ally with the membrane thickness and can be orders of IgG enters the capsules, islet destruction does not occur in 
magnitude greater than that of the sodium akinate/PolY(L- 4o vivo, presumably because entry of complement (required for 
lysine) (sA/PLL/sA) microcaPsules (data not shown). FIG. cell lysis by IgG) would be prevented (based on capsule PSD 
5 also shows that initial membrane thickness decreases as and predicted size of complement), 
the capsules are treated with the chelating agent, and this Viability and function of rat pancreatic islets enclosed in 
process continues in PBS. In addition, the formation of a thin the capsules with 230 m a  exclusion limit was tested in vitro 
distinct layer on the inside of the capsular membrane was (FIG. 9). Using a cell perifusion apparatus, glucose- 
observed after a few hours of storage in PBS. stimulated insulin secretion by rat pancreatic islets, enclosed 
within capsules with a dextran exclusion limit of 230 kDa, 
was well-preserved barring a slight delay in comparison 
with unencapsulated islets (FIG. 9). Islets enclosed in cap- 
sules with differing wall thicknesses, but the same 230 kDa 
EXAMPLE 13 
out the experiment, the data in TABLE 111 show the effect of 
of preparation (after the first wash with PBS), Above a 
meability2 a series of capsules with a range of 
sion measurement) was and characterized. 
1s 
TABLE I11 
Capsule size at different stages of capsule processing. 
Capsule size [mm) 
20 
Sodium citrate Storage in PBS Time 
2s  
4s  
EXAMPLE 11 
Mechanical Strength 
strength Of capsu1es was measured by 
placing an increasing uniaxial load on the capsule until the 50 exclusion limit, showed a similar insulin response, 
capsule burst. The capsule mechanical strength, a function 
of membrane thickness, can be adjusted from a fraction of 
a gram to tens of gram load to meet the needs of transplan- 
tation without altering the permeability of the capsule. FIG. Prior to transplantation of encapsulated islets into 
6 is a plot of the rupture load the product of ss animals, extensive biocompatibility testing of empty cap- 
membrane thickness and capsule size and demonstrates that sules was Performed. Capsules were transplanted into the 
the capsule of the present invention has much greater peritoneal cavity of healthy mice to study biocompatibility 
flexibility in mechanical strength than capsules formulated and later retrieved to study the tissue reaction and fibrosis on 
with the widely-used sodium a~ginate/po~y~ysine system, the capsule surface. The experimental results were surpris- 
The slope of the curve represents the rupture stress and 60 ing in that capsules similar in physical appearance, mechani- 
thereby indirectly the inherent strength of the capsular cal strength, and permeability, exhibited drastic differences 
membrane (ref. 34). in biocompatibility. For example, two capsules, which were 
prepared under identical processing steps and differed only 
EXAMPLE 12 in PMCG concentration-1% PMCG versus 1.8%- 
65 demonstrated a remarkable difference in the ability to stimu- 
late fibrosis on the capsule surface (FIG. 10). These data 
suggest that a narrow window of operation parameters exist, 
The 
Animal Trials: Empty Capsules 
Diffusion Characteristics of Microcapsules 
Measurement of capsule permeability was performed by 
utilizing two complementary methods: 1) size exclusion 
5,997,900 
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both in chemistry and capsule processing, and that minor 13. Soon-Shiong, P., Feldman, E., Nelson, R., Heintz, R., 
variations may have strong impact on biocompatibility. Yao, Q., Yao, Z., et al. 1993. Long-term reversal of 
diabetes by the injection of immunoprotected islets. Pro- 
ceedings of the National Academy of Sciences of the EXAMPLE 14 
United States of America 90, 5843-5847. Diabetes Reversal Encapsulated rat islets readily reversed chemically- 14. Soon-Shiong, P., Heintz, R. E., Merideth, N., Yao, Q. X., induced diabetes in mice (strepzotocin-induced) and islet 
type 1 diabetic patient after encapsulated islet transplan- Similar studies were performed with diabetic NOD female tation. Lancet 343, 950-951. mice and diabetes was reversed for up to 180 days (FIG. 15. Scharp, D. W., Swanson, C. J., Olack, B. J., Latta, P. P., 11B). The encapsulated islets, transplanted into the perito- i o  Hegre, 0. D., Doherty, E. J., et al. 1994. Protection of neal cavity, are free-floating, quite biocompatible and show encapsulated human islets implanted without immuno- no significant fibrosis or tissue reaction (FIG. 12). Encap- 
in nondiabetic control subjects. Diabetes 43, 1167-1170. 
16. Weber, C., Krekun, SECONDS., Koschitzky, T., ability to secrete insulin following glucose stimulation (FIG. 
Zabinski, SECONDS., D'Agati, V., Hardy, M., et al. 12A). The eventual decrease in effectiveness of encapsulated islets transplanted into animals with chemically-induced 
diabetes did not result from capsule rupture or from an 1991. Prolonged functional survival of rat-to-NOD mouse islet xenografts by ultraviolet-B (UV-B) irradiation plus immune attack. Capsules retrieved from those animals were 
free-floating and their surface was free of fibrosis, Thus, the microencapsulation of donor islets. Transplantation Pro- ceedings 23, 764-766. decrease likely resulted from islet death within the capsule, 
because of soluble immune factors (cytokines). In contrast, c. 8~ Brunetti, p. 1996. Coherent microcapsules for pan- 
the decrease in effectiveness of encapsulated islets trans- creatic islet transplantation: a new approach for bioarti- 
or autoimmune attack. Capsules ultimately retrieved from 812-813. 
those animals were clumped and demonstrated marked zs 18. Lim, F. & Sun, A. M. 1980. Microencapsulated islets as 
fibrosis around the capsule surface. bioartificial endocrine pancreas. Science 210, 908-910. 
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function was maintained for at least 4-6 months (FIG, 11A). yaO, z., T., et 1994. Insulin independence in a 
sulated islets have long-term function as assessed by their suppression in patients with type I Or type 'I diabetes and 
possibly from a nutrient deficiency or from islet toxicity 2o 17. Calafiore, R., Basta, G., Osticioli, L., Luca, G., Tortoioli, 
planted into NOD mice may have resulted from an immune ficial pancreas. Proceedings 28, 
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chemical and physical properties of alginate gel beads, encompassed within the spirit of the invention as defined by 
Biotechnol. Bioeng., 33, 79-89 (1989). the scope of the claims. 
31. 0 SmidsrBd, Solution properties of alginate, Carbohyd. What is claimed is: 
Res., 13, 359-372 (1970). 1. A composition of matter for the encapsulation of cells 
32. K Eshino, T. Kawai, T. Nose, M. Saitoh, and K. 5 comprising high viscosity sodium alginate, cellulose sulfate, 
Kamide, Dilute solution properties of sodium cellulose and a multi-component polycation, wherein said polycation 
disulfate, Eur: Polym. J., 17, 623-630 (1981). is selected from the group consisting of poly(methy1ene-co- 
33. J. J. Waldmann, Compositions of inorganic-organic alloy guanidine)hydrochloride, calcium chloride and sodium 
with high nitrogen content polymers and their chloride, 
2. The composition of matter of claim 1, wherein said manufacture, U.S. Pat. No. 4,891,422 (1990). 34. Lardner, T. & Pujara, P. 1980. Compression of spherical high viscosity sodium alginate and said cellulose sulfate are cells. Mechanics Today 161-176. 
in a ratio of approximately 1: l .  35. Brissova, M., Lacik, I., Powers, A. C. & Wang, T. G. 3. The composition of matter of claim 1, wherein said 1996. Evaluation of microcapsule permeability via ins- size exclusion chromatography, Analytical Bio- 15 high viscosity sodium alginate and said cellulose sulfate are 
at a total concentration of 0.8 wt-% to 2.4 wt-%. chemistry 242, 104-111. 
calibration of size-exc~usion chromatography for proteins high viscosity sodium alginate and said cellulose sulfate are 
molecular-mass proteins titin and nebulin. Journal of 20 5 .  The ComPosition of matter of claim 1, wherein each 
Chromatography A654, 229-246. component of said multi-component polycation is at a 
37. Sun, Y. L., Ma, X., Zhou, D., Vacek, I. & Sun, A. M. concentration Of 0.5 wt-% to 5.0 wt-%. 
1 9 9 3 .  P o r c i n e  p a n c r e a t i c  i s l e t s :  i s o l a t i o n ,  6. The composition of matter of claim 5, wherein each 
microencapsulation, and xenotransplantation. Artificial Of said multi-comPonent PolYcation is at a 
Organs 17, 727-733. 
hy patents or publications mentioned in this specifics- 7. The composition of matter of claim 1 wherein said 
which the invention pertains, These patents and publications tration of about 0.5 wt-% to 5.0 wt-%, calcium chloride is at 
are herein incorporated by reference to the Same extent as if a concentration of about 0.5 wt-% to 5.0 wt-%, and sodium 
each individual publication was specifically and individually 30 chloride is at a concentration of about 0.5 wt-% to 5.0 wt-%. 
indicated to be incorporated by reference. 8. The composition of matter of claim 7, wherein said 
one skilled in the art will readily appreciate that the poly(methy1ene-co-guanidine)hydrochloride is at a concen- 
present invention is well adapted to carry out the objects and tration of about 1.8 wt-%., calcium chloride is at a concen- 
inherent therein. The present examples along with the 35 concentration Of about 0.9 wt-%. 
methods, procedures, treatments, molecules, and specific 
preferred embodiments, are exemplary, and are not intended 
as limitations on the scope of the invention. Changes therein 
and other uses will occur to those skilled in the art which are 
lo 
36. Nave, R., Weber, K. & Potschka, M. 1993. Universal 4. The composition of matter of 3, wherein said 
in guanidinium hydrochoride including the high- at a total concentration of 1.0 wt-% to 1.2 wt-%. 
25 concentration of 0.8 wt-% to 2.8 wt-%. 
tion are indicative of the levels of those skilled in the art to poly(methylene-co-guanidine)hydrochloride is at a concen- 
obtain the ends and advantages mentioned, as well as those tration of about 1.0 wt-%, and sodium chloride is at a 
9. The composition of claim 1 wherein the microcapsule 
compounds described herein are presently representative of formed by said has a diameter Of from about 
0.5 mm to about 2.0 mm. 
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